유럽의 오피오이드 시장 예측(-2030년) : 지역별 분석 - 제품별, 용도별, 투여 경로별, 유통 채널별

The Europe opioids market was valued at US$ 4,553.86 million in 2022 and is expected to reach US$ 5,237.72 million by 2030; it is estimated to register a CAGR of 1.8% from 2022 to 2030.

Surging Chronic Pain Incidence Drive Europe Opioids Market

Chronic diseases such as cardiovascular disease, cancer, musculoskeletal diseases, and neurovascular diseases critically affect a person's health by lowering immunity. Moreover, many patients suffering from these conditions experiences chronic pain. The diseases mentioned above are most common in adults and the geriatric population. Nevertheless, cases of these diseases are noticeably growing among children as well. Chronic pain is also common among sportspersons, athletes, and individuals living with past injuries. According to a study published in the NCBI (i.e., National Center for Biotechnology Information), 20% of adults suffer from pain worldwide, and 10% are newly diagnosed with chronic pain per year. While pain affects all populations, regardless of sex, race/ethnicity, income, age, or geography, it is not distributed equally across the world. Prescription opioids, including hydrocodone, oxycodone, and morphine, are potent pain-reducing medications that are used to treat pain caused by injuries, surgeries, and health conditions such as cancer and arthritis. Increased opioid prescribing practices can be attributed to the insurance reimbursement programs that incentivize opioids over alternative pain treatments, cost structures that encourage more efficient care, and evaluations that combine patient satisfaction with effective pain management. Therefore, owing to the advantage of opioids in pain management, the demand is rising among patients with chronic diseases.

Europe Opioids Market Overview

The Europe opioids market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the Europe opioids market and is expected to experience strong market growth during the forecast period. The market growth in the region is mainly attributed to the rising prevalence of diseases that cause chronic pain (such as arthritis, lower back pain, and fibromyalgia) and the surging availability of medications to treat addiction to opioid drugs (such as heroin). For instance, methadone is the most prescribed opioid agonist in Europe and is used in 75% of patients for opioid agonist maintenance treatment. Buprenorphine is the second most used opioid agonist in the region. However, it is one of the most often used opioid maintenance treatments in Croatia, Cyprus, the Czech Republic, Finland, France, and Sweden. Codeine is the primary agonist used in Cyprus and Germany, whereas diacetylmorphine is the one that is commonly used in Belgium, Denmark, Germany, the Netherlands, Spain, the UK, and Ireland.

Europe Opioids Market Revenue and Forecast to 2030 (US$ Million)

Europe Opioids Market Segmentation

The Europe opioids market is categorized into product, application, route of administration, distribution channel, and country.

Based on product, the Europe opioids market is segmented immediate release short acting opioid and extended release long acting opioid. The immediate release short acting opioid segment held a larger market share in 2022. The immediate release short acting opioid is further sub segmented into oxycodone, hydrocodone, tramadol, codeine, propoxyphene, and others. The extended release long acting opioid is further sub segmented into oxycodone, fentanyl, morphine, methadone, and others.

In terms of application, the Europe opioids market is categorized into pain management, anesthesia, diarrhea suppression, cough suppression, de-addiction, and others. The pain management segment held the largest market share in 2022.

By route of administration, the Europe opioids market is segmented into oral, injectable, and transdermal patch. The oral segment held the largest market share in 2022.

By distribution channel, the Europe opioids market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment held a larger market share in 2022.

By country, the Europe opioids market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe opioids market share in 2022.

Endo International plc, Mallinckrodt Plc, Neuraxpharm Pharmaceuticals SL, Hikma Pharmaceuticals Plc, Rusan Pharma Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Europe opioids market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Europe Opioids Market - Key Market Dynamics

• 4.1 Market Drivers
  • 4.1.1 Surging Chronic Pain Incidence
  • 4.1.2 Increasing Geriatric Population
• 4.2 Market Restraints
  • 4.2.1 Increasing Drug Abuse
• 4.3 Market Opportunities
  • 4.3.1 Strategic Initiatives by Market Players
• 4.4 Impact of Drivers and Restraints:

5. Opioids Market - Europe Analysis

• 5.1 Europe Opioids Market Overview
• 5.2 Europe Opioids Market Revenue (US$ Million), 2020-2030
• 5.3 Europe Opioids Market Forecast Analysis

6. Europe Opioids Market Analysis - by Product

• 6.1 Immediate Release Short Acting Opioid
  • 6.1.1 Overview
  • 6.1.2 Immediate Release Short Acting Opioid: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.1.2.1 Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid
• 6.2 Extended Release Long-Acting Opioid
  • 6.2.1 Overview
  • 6.2.2 Extended Release Long-Acting Opioid: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.2.2.1 Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. Europe Opioids Market Analysis - by Application

• 7.1 Pain Management
  • 7.1.1 Overview
  • 7.1.2 Pain Management: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.2 Anesthesia
  • 7.2.1 Overview
  • 7.2.2 Anesthesia: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.3 Diarrhea Suppression
  • 7.3.1 Overview
  • 7.3.2 Diarrhea Suppression: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Cough Suppression
  • 7.4.1 Overview
  • 7.4.2 Cough Suppression: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 De-Addiction
  • 7.5.1 Overview
  • 7.5.2 De-Addiction: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 7.6 Others
  • 7.6.1 Overview
  • 7.6.2 Others: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Opioids Market Analysis - by Route of Administration

• 8.1 Oral
  • 8.1.1 Overview
  • 8.1.2 Oral: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 8.2 Injectable
  • 8.2.1 Overview
  • 8.2.2 Injectable: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 8.3 Transdermal Patch
  • 8.3.1 Overview
  • 8.3.2 Transdermal Patch: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Opioids Market Analysis - by Distribution Channel

• 9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Hospital Pharmacies: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
• 9.2 Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Retail Pharmacies: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Opioids Market - Country Analysis

• 10.1 Europe
  • 10.1.1 Europe: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)
    • 10.1.1.1 Europe: Opioids Market - Revenue and Forecast Analysis - by Country
    • 10.1.1.2 United Kingdom: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.2.1 United Kingdom: Europe Opioids Market Breakdown, by Product
      • 10.1.1.2.2 United Kingdom: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.2.3 United Kingdom: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.2.4 United Kingdom: Europe Opioids Market Breakdown, by Application
      • 10.1.1.2.5 United Kingdom: Europe Opioids Market Breakdown, by Route of Administration
      • 10.1.1.2.6 United Kingdom: Europe Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.3 Germany: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.3.1 Germany: Europe Opioids Market Breakdown, by Product
      • 10.1.1.3.2 Germany: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.3.3 Germany: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.3.4 Germany: Europe Opioids Market Breakdown, by Application
      • 10.1.1.3.5 Germany: Europe Opioids Market Breakdown, by Route of Administration
      • 10.1.1.3.6 Germany: Europe Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.4 France: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.4.1 France: Europe Opioids Market Breakdown, by Product
      • 10.1.1.4.2 France: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.4.3 France: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.4.4 France: Europe Opioids Market Breakdown, by Application
      • 10.1.1.4.5 France: Europe Opioids Market Breakdown, by Route of Administration
      • 10.1.1.4.6 France: Europe Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.5 Italy: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.5.1 Italy: Europe Opioids Market Breakdown, by Product
      • 10.1.1.5.2 Italy: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.5.3 Italy: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.5.4 Italy: Europe Opioids Market Breakdown, by Application
      • 10.1.1.5.5 Italy: Europe Opioids Market Breakdown, by Route of Administration
      • 10.1.1.5.6 Italy: Europe Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.6 Spain: Europe Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.6.1 Spain: Europe Opioids Market Breakdown, by Product
      • 10.1.1.6.2 Spain: Europe Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.6.3 Spain: Europe Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.6.4 Spain: Europe Opioids Market Breakdown, by Application
      • 10.1.1.6.5 Spain: Europe Opioids Market Breakdown, by Route of Administration
      • 10.1.1.6.6 Spain: Europe Opioids Market Breakdown, by Distribution Channel
    • 10.1.1.7 Rest of Europe: Opioids Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.7.1 Rest of Europe: Opioids Market Breakdown, by Product
      • 10.1.1.7.2 Rest of Europe: Opioids Market Breakdown, by Immediate Release Short Acting Opioid
      • 10.1.1.7.3 Rest of Europe: Opioids Market Breakdown, by Extended Release Long-Acting Opioid
      • 10.1.1.7.4 Rest of Europe: Opioids Market Breakdown, by Application
      • 10.1.1.7.5 Rest of Europe: Opioids Market Breakdown, by Route of Administration
      • 10.1.1.7.6 Rest of Europe: Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in Opioids Market
• 11.3 Organic Growth Strategies
  • 11.3.1 Overview
• 11.4 Inorganic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Endo International plc
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Mallinckrodt Plc
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Neuraxpharm Pharmaceuticals SL
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Hikma Pharmaceuticals Plc
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Rusan Pharma Ltd
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Teva Pharmaceutical Industries Ltd
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms